Diagnostic accuracy of a panel of immunohistochemical and molecular markers to distinguish Merkel cell carcinoma from other neuroendocrine carcinomas.


Journal

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605

Informations de publication

Date de publication:
04 2019
Historique:
received: 14 07 2018
accepted: 03 09 2018
revised: 02 09 2018
pubmed: 24 10 2018
medline: 18 12 2019
entrez: 24 10 2018
Statut: ppublish

Résumé

Merkel cell carcinoma is a rare neuroendocrine carcinoma of the skin mostly induced by Merkel cell polyomavirus integration. Cytokeratin 20 (CK20) positivity is currently used to distinguish Merkel cell carcinomas from other neuroendocrine carcinomas. However, this distinction may be challenging in CK20-negative cases and in cases without a primary skin tumor. The objectives of this study were first to evaluate the diagnostic accuracy of previously described markers for the diagnosis of Merkel cell carcinoma and second to validate these markers in the setting of difficult-to-diagnose Merkel cell carcinoma variants. In a preliminary set (n = 30), we assessed optimal immunohistochemical patterns (CK20, thyroid transcription factor 1 [TTF-1], atonal homolog 1 [ATOH1], neurofilament [NF], special AT-rich sequence-binding protein 2 [SATB2], paired box protein 5, terminal desoxynucleotidyl transferase, CD99, mucin 1, and Merkel cell polyomavirus-large T antigen) and Merkel cell polyomavirus load thresholds (real-time PCR). The diagnostic accuracy of each marker was then assessed in a validation set of 103 Merkel cell carcinomas (9 CK20-negative cases and 15 cases without a primary skin tumor) and 70 extracutaneous neuroendocrine carcinoma cases. The most discriminant markers for a diagnosis of Merkel cell carcinoma were SATB2, NF expression, and Merkel cell polyomavirus DNA detection (positive likelihood ratios: 36.6, 44.4, and 28.2, respectively). Regarding Merkel cell carcinoma variants, cases without a primary skin tumor retained a similar immunohistochemical  profile and CK20-negative tumors displayed a different profile (decrease frequency of NF and SATB2 expression), but Merkel cell polyomavirus DNA remained detected (78% of cases by qPCR). Moreover, 8/9 (89%) CK20-negative Merkel cell carcinoma cases but only 3/61 (5%) CK20-negative extracutaneous neuroendocrine cases were positive for at least one of these markers. In conclusion, detection of SATB2 and NF expression and Merkel cell polyomavirus DNA helps distinguish between Merkel cell carcinoma classical and variant cases and extracutaneous neuroendocrine carcinomas.

Identifiants

pubmed: 30349028
doi: 10.1038/s41379-018-0155-y
pii: S0893-3952(22)01459-4
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

499-510

Auteurs

Thibault Kervarrec (T)

Department of Pathology, Université de Tours, CHU de Tours, Avenue de la République, 37170, Chambray-les-tours, France.
"Biologie des infections à polyomavirus" team, UMR INRA ISP 1282, Université de Tours, 31, Avenue Monge, 37200, Tours, France.
Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Josef-Schneider-Straße 2, 97080, Würzburg, Germany.

Anne Tallet (A)

Platform of Somatic Tumor Molecular Genetics, Université de Tours, CHU de Tours, Avenue de la République, 37170, Chambray-les-tours, France.

Elodie Miquelestorena-Standley (E)

Department of Pathology, Université de Tours, CHU de Tours, Avenue de la République, 37170, Chambray-les-tours, France.

Roland Houben (R)

Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Josef-Schneider-Straße 2, 97080, Würzburg, Germany.

David Schrama (D)

Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Josef-Schneider-Straße 2, 97080, Würzburg, Germany.

Thilo Gambichler (T)

Department of Dermatology, Venereology and Allergology, University Hospital Bochum, GudrunStraße 5, 44791, Bochum, Germany.

Patricia Berthon (P)

"Biologie des infections à polyomavirus" team, UMR INRA ISP 1282, Université de Tours, 31, Avenue Monge, 37200, Tours, France.

Yannick Le Corre (Y)

Dermatology Department, LUNAM Université, CHU Angers, 4 rue Larrey, 49933, Angers, France.

Ewa Hainaut-Wierzbicka (E)

Dermatology Department, Université de Poitiers, CHU de Poitiers, 2 rue de la Milétrie, 86021, Poitiers, France.

Francois Aubin (F)

Dermatology Department, Université de Franche Comté, CHU Besançon, EA3181, IFR133, 2 Boulevard Fleming, 25030, Besançon, France.

Guido Bens (G)

Dermatology Department, CHR d'Orléans, 14 Avenue de l'hôpital, 45100, Orléans, France.

Flore Tabareau-Delalande (F)

Department of Pathology, CHR d'Orléans, 14 Avenue de l'hôpital, 45100, Orléans, France.

Nathalie Beneton (N)

Dermatology Department, CHR Le Mans, 194 Avenue Rubillard, 72037, Le Mans Cedex 09, France.

Gaëlle Fromont (G)

Department of Pathology, Université de Tours, CHU de Tours, Boulevard Tonnellé, 37044, Tours, France.

Flavie Arbion (F)

Department of Pathology, Université de Tours, CHU de Tours, Boulevard Tonnellé, 37044, Tours, France.

Emmanuelle Leteurtre (E)

Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPARC - Jean-Pierre Aubert Research Center-, F-59000, Lille, France.

Antoine Touzé (A)

"Biologie des infections à polyomavirus" team, UMR INRA ISP 1282, Université de Tours, 31, Avenue Monge, 37200, Tours, France.

Mahtab Samimi (M)

"Biologie des infections à polyomavirus" team, UMR INRA ISP 1282, Université de Tours, 31, Avenue Monge, 37200, Tours, France.
Dermatology Department, Université de Tours, CHU de Tours, Avenue de la République, 37170, Chambray-les-tours, France.

Serge Guyétant (S)

Department of Pathology, Université de Tours, CHU de Tours, Avenue de la République, 37170, Chambray-les-tours, France. serge.guyetant@univ-tours.fr.
"Biologie des infections à polyomavirus" team, UMR INRA ISP 1282, Université de Tours, 31, Avenue Monge, 37200, Tours, France. serge.guyetant@univ-tours.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH